Team
Team
BroadenBio Co., Ltd. (BroadenBio) received the new drug clinical trial approval notice for the Class I investigational new drug BB102 from the Center of Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on July 26th, 2022. The first-in-human Phase 1 clinical trials for advanced solid tumors in China will be initiated soon.
BB102 is an innovative small molecule kinase inhibitor discovered and being developed by BroadenBio for the treatment of advanced solid tumors driven by abnormal oncogenic genes. Besides its novel mechanism of action, high selectivity, good safety, and over advantages, BB102 shows promising efficacy to mutation-driven tumors, and is expected to benefit more cancer patients.
address：
A1-602, 88 Kechuang 6th Street, BDA, Beijing 100176
phone：
Copyright ©2019 BroadenBio